| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Aromatase
Multiple targets including 17β-hydroxysteroid dehydrogenase (17β-HSD), aromatase, 5-lipoxygenase (5-LOX), and taste receptor type 2 member 14 (TAS2R14). Eriodictyol chalcone is a natural product exhibiting inhibitory activity against 17β-HSD and aromatase. It also inhibits bovine liver arginase and acts as an agonist of TAS2R14. |
|---|---|
| ln Vitro |
Eriodictyol chalcone exhibits potent inhibition of 5-lipoxygenase (5-LOX) with an IC50 of 0.043 µM in a cell-free assay. It possesses both anti-aromatase and anti-17β-HSD activity. The compound inhibits bovine liver arginase and acts as an agonist of TAS2R14. It has anti-plasmodial effects on Plasmodium falciparum growth.
|
| ln Vivo |
In vivo, Eriodictyol chalcone would be expected to exert biological effects through its multiple targets, including modulation of steroid hormone metabolism (via aromatase and 17β-HSD inhibition), leukotriene biosynthesis (via 5-LOX inhibition), and taste signaling (via TAS2R14 agonism). Its effects would be assessed in animal models of inflammation, cancer, and metabolic disorders. Specific in vivo data is limited in the available literature.
|
| Enzyme Assay |
In vitro enzyme activity assays for Eriodictyol chalcone involve measuring its ability to inhibit target enzymes. For 5-LOX inhibition, the enzyme is incubated with arachidonic acid substrate in the presence of increasing concentrations of the compound, and leukotriene production is measured. For aromatase and 17β-HSD inhibition, enzyme activity assays are performed using relevant substrates and measuring product formation.
|
| Cell Assay |
In vitro cellular assays for Eriodictyol chalcone involve treating relevant cell lines (e.g., cancer cells, immune cells) with the compound and measuring its effects on cell proliferation, inflammation, and signaling pathways. The compound's anti-plasmodial effects can be assessed in Plasmodium falciparum cultures. Its effects on steroid hormone metabolism can be evaluated in hormone-responsive cell lines.
|
| Animal Protocol |
In vivo efficacy of Eriodictyol chalcone would be evaluated in animal models of inflammation, cancer, and metabolic disorders. The compound could be administered orally or via injection. Efficacy endpoints would depend on the disease model and could include tumor growth inhibition, reduction of inflammatory markers, and modulation of metabolic parameters. Specific in vivo data is limited.
|
| ADME/Pharmacokinetics |
Eriodictyol chalcone has a molecular weight of 288.25 g/mol and a molecular formula of C15H12O6. It has a melting point of 157-158°C and density of 1.584 g/cm3. The compound is slightly soluble in water (1.2 g/L at 25°C) and should be stored under nitrogen, protected from direct sunlight and moisture. As a natural product, its pharmacokinetic properties would be characteristic of flavonoids.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for Eriodictyol chalcone in the provided literature. As a naturally occurring flavonoid, it is generally considered to have low toxicity. However, its safety profile has not been systematically evaluated. Standard preclinical safety studies would be required to evaluate its safety for potential therapeutic applications.
|
| References | |
| Additional Infomation |
2',3,4,4',6'-Pentahydroxychalcone is a chalcone compound with a structure consisting of chalcones substituted with hydroxyl groups at the 2', 3, 4, 4', and 6' positions. Functionally, it is related to chalcones. It is the conjugate acid of 2',3,4,4',6'-Pentahydroxychalcone (1-). The detection of 2',3,4,4',6'-Pentahydroxychalcone in limonium has been reported in the literature, with relevant data available.
Eriodictyol chalcone (CAS#: 14917-41-0) is a naturally occurring chalcone with a molecular formula of C15H12O6 and a molecular weight of 288.25. It possesses anti-aromatase, anti-17β-HSD, and 5-LOX inhibitory activities. It has anti-plasmodial effects on Plasmodium falciparum and acts as an agonist of TAS2R14. The compound is a research tool for studying inflammation, cancer, and metabolic disorders. It is not approved for clinical use. |
| Molecular Formula |
C15H12O6
|
|---|---|
| Exact Mass |
288.063
|
| CAS # |
14917-41-0
|
| PubChem CID |
5461154
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.584g/cm3
|
| Boiling Point |
595.9ºC at 760mmHg
|
| Melting Point |
157-158 ºC
|
| Flash Point |
328.2ºC
|
| Vapour Pressure |
8.52E-15mmHg at 25°C
|
| Index of Refraction |
1.782
|
| LogP |
2.11
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
384
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C=C1/C=C/C(=O)C2=C(C=C(C=C2O)O)O)O)O
|
| InChi Key |
CRBYNQCDRNZCNX-DUXPYHPUSA-N
|
| InChi Code |
InChI=1S/C15H12O6/c16-9-6-13(20)15(14(21)7-9)11(18)4-2-8-1-3-10(17)12(19)5-8/h1-7,16-17,19-21H/b4-2+
|
| Chemical Name |
(E)-3-(3,4-dihydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
